Literature DB >> 8956017

Systemic fat embolism and pulmonary hypertension in sickle cell disease.

O Castro1.   

Abstract

Systemic fat embolism, a relatively rare complication of sickle cell disease, is difficult to diagnose and it is often fatal. A high index of suspicion and early transfusion therapy may provide the best chance for recovery. Sickle cell-related pulmonary hypertension can be documented by cardiac catheterization but has no proven treatment. Patients with this complication are usually adults, have a poor prognosis, and may be considered for hydroxyurea treatment. Administration of vasodilators, anticoagulation, or oxygen may be beneficial in selected individuals.

Entities:  

Mesh:

Year:  1996        PMID: 8956017     DOI: 10.1016/s0889-8588(05)70401-9

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  13 in total

1.  Cardiopulmonary complications of sickle cell disease: role of nitric oxide and hemolytic anemia.

Authors:  Mark T Gladwin; Gregory J Kato
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2005

Review 2.  Pathophysiology of Sickle Cell Disease.

Authors:  Prithu Sundd; Mark T Gladwin; Enrico M Novelli
Journal:  Annu Rev Pathol       Date:  2018-10-17       Impact factor: 23.472

3.  Pulmonary hypertension in hemolytic disorders: pulmonary vascular disease: the global perspective.

Authors:  Roberto F Machado; Mark T Gladwin
Journal:  Chest       Date:  2010-06       Impact factor: 9.410

4.  Vascular TSP1-CD47 signaling promotes sickle cell-associated arterial vasculopathy and pulmonary hypertension in mice.

Authors:  Enrico M Novelli; Lynda Little-Ihrig; Heather E Knupp; Natasha M Rogers; Mingyi Yao; Jeffrey J Baust; Daniel Meijles; Claudette M St Croix; Mark A Ross; Patrick J Pagano; Evan R DeVallance; George Miles; Karin P Potoka; Jeffrey S Isenberg; Mark T Gladwin
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2019-03-20       Impact factor: 5.464

Review 5.  Pulmonary manifestations of sickle cell disease.

Authors:  A K Siddiqui; S Ahmed
Journal:  Postgrad Med J       Date:  2003-07       Impact factor: 2.401

6.  Pulmonary hypertension in children and adolescents with sickle cell disease.

Authors:  O C Onyekwere; A Campbell; M Teshome; S Onyeagoro; C Sylvan; A Akintilo; S Hutchinson; G Ensing; P Gaskin; G Kato; S Rana; J Kwagyan; V Gordeuk; J Williams; O Castro
Journal:  Pediatr Cardiol       Date:  2007-08-07       Impact factor: 1.655

7.  Identification of genetic polymorphisms associated with risk for pulmonary hypertension in sickle cell disease.

Authors:  Allison E Ashley-Koch; Laine Elliott; Melanie E Kail; Laura M De Castro; Jude Jonassaint; Terry L Jackson; Jennifer Price; Kenneth I Ataga; Marc C Levesque; J Brice Weinberg; Eugene P Orringer; Ann Collins; Jeffery M Vance; Marilyn J Telen
Journal:  Blood       Date:  2008-01-10       Impact factor: 22.113

8.  Clinical and electrocardiographic evaluation of sickle-cell anaemia patients with pulmonary hypertension.

Authors:  N I Oguanobi; E C Ejim; B C Anisiuba; B J C Onwubere; S O Ike; O G Ibegbulam; O Agwu
Journal:  ISRN Hematol       Date:  2012-03-25

Review 9.  Sildenafil in the treatment of pulmonary hypertension.

Authors:  Christopher F Barnett; Roberto F Machado
Journal:  Vasc Health Risk Manag       Date:  2006

10.  Bone marrow necrosis and fat embolism syndrome: a dreadful complication of hemoglobin sickle cell disease.

Authors:  Eduardo Pelegrineti Targueta; André Carramenha de Góes Hirano; Fernando Peixoto Ferraz de Campos; João Augusto Dos Santos Martines; Silvana Maria Lovisolo; Aloisio Felipe-Silva
Journal:  Autops Case Rep       Date:  2017-12-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.